X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (18) 18
humans (16) 16
pharmacology & pharmacy (10) 10
animals (9) 9
clopidogrel (7) 7
platelet aggregation inhibitors - metabolism (7) 7
prasugrel hydrochloride (7) 7
piperazines - metabolism (6) 6
thiophenes - metabolism (6) 6
male (5) 5
mice (5) 5
microsomes, liver - enzymology (5) 5
pharmacokinetics (5) 5
thienopyridine (5) 5
ticlopidine - analogs & derivatives (5) 5
antigens (4) 4
cell line, tumor (4) 4
enzyme inhibitors - pharmacology (4) 4
immunology (4) 4
immunotherapy (4) 4
microsomes, liver - drug effects (4) 4
piperazines - pharmacology (4) 4
platelet aggregation inhibitors - pharmacology (4) 4
prasugrel (4) 4
thiophenes - pharmacology (4) 4
analysis (3) 3
antiplatelet agent (3) 3
article (3) 3
aryl hydrocarbon hydroxylases - antagonists & inhibitors (3) 3
cytochrome p-450 cyp2b6 (3) 3
cytochrome p-450 enzyme system - metabolism (3) 3
drb1 protein (3) 3
female (3) 3
glutathione - metabolism (3) 3
histocompatibility antigen hla (3) 3
hla (3) 3
hla-drb1 chains - chemistry (3) 3
hla-drb1 chains - metabolism (3) 3
ifn-γ (3) 3
in-vitro (3) 3
kinetics (3) 3
liver (3) 3
mice, inbred balb c (3) 3
mice, nude (3) 3
molecular dynamics (3) 3
molecular dynamics simulation (3) 3
oncology (3) 3
oxidation-reduction (3) 3
p2y receptor (3) 3
peptides (3) 3
platelet aggregation inhibitors - pharmacokinetics (3) 3
rats (3) 3
skin and connective tissue diseases (3) 3
tandem mass spectrometry (3) 3
ticlopidine (3) 3
ticlopidine - metabolism (3) 3
allergy (2) 2
antiaggregating activity (2) 2
antibodies, monoclonal - pharmacology (2) 2
antibodies, monoclonal, humanized - pharmacology (2) 2
antibody-drug conjugate (2) 2
aspirin-treated patients (2) 2
binding (2) 2
biochemistry & molecular biology (2) 2
biotransformation (2) 2
biotransformation - physiology (2) 2
breast cancer (2) 2
bupropion hydroxylation (2) 2
camptothecin - analogs & derivatives (2) 2
camptothecin - pharmacology (2) 2
cancer (2) 2
cancer therapies (2) 2
cedar pollen allergen (2) 2
cell line (2) 2
cell proliferation - drug effects (2) 2
chromatography, gel (2) 2
chromatography, liquid (2) 2
clinical trials (2) 2
coronary-artery-disease (2) 2
cytochrome p-450 cyp2c19 (2) 2
diphosphate-receptor antagonists (2) 2
disposition (2) 2
dogs (2) 2
dose-response relationship, drug (2) 2
epidermal growth factor (2) 2
expression (2) 2
glutaredoxins - antagonists & inhibitors (2) 2
glutaredoxins - metabolism (2) 2
health aspects (2) 2
healthy-subjects (2) 2
hepatotoxicity (2) 2
hydrolysis (2) 2
ifn-gamma (2) 2
ige (2) 2
igg1 (2) 2
igg2a (2) 2
il-4 (2) 2
immune response (2) 2
immunoconjugates - pharmacology (2) 2
immunostimulatory dna sequence (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer Science, ISSN 1347-9032, 07/2016, Volume 107, Issue 7, pp. 1039 - 1046
Antibody–drug conjugates deliver anticancer agents selectively and efficiently to tumor tissue and have significant antitumor efficacy with a wide therapeutic... 
topoisomerase I inhibitor | HER | bystander killing | Antibody‐drug conjugate | T-DM | HER2 | Antibody-drug conjugate | HODGKINS LYMPHOMA | GEMTUZUMAB OZOGAMICIN | ADVANCED BREAST-CANCER | BRENTUXIMAB VEDOTIN | ACUTE MYELOID-LEUKEMIA | TRASTUZUMAB EMTANSINE | CHALLENGES | THERAPY | ONCOLOGY | EXPRESSION | CATHEPSIN-B | Receptor, ErbB-2 - genetics | Breast Neoplasms - immunology | Humans | Stomach Neoplasms - pathology | Maytansine - pharmacology | Immunoconjugates - immunology | Breast Neoplasms - enzymology | Immunoconjugates - pharmacology | Topoisomerase I Inhibitors - pharmacology | Neoplasms - genetics | Antibodies, Monoclonal, Humanized - pharmacology | Female | Camptothecin - immunology | Receptor, ErbB-2 - immunology | Camptothecin - analogs & derivatives | Stomach Neoplasms - enzymology | Stomach Neoplasms - genetics | Maytansine - analogs & derivatives | Neoplasms - enzymology | Stomach Neoplasms - immunology | Animals | Breast Neoplasms - genetics | Bystander Effect - drug effects | Breast Neoplasms - pathology | Mice, Nude | Neoplasms - immunology | Cell Membrane Permeability - drug effects | Cell Line, Tumor | Cell Proliferation - drug effects | Mice | Mice, Inbred BALB C | Antibodies, Monoclonal, Humanized - immunology | Neoplasms - pathology | Camptothecin - pharmacology | Maytansine - immunology | Trastuzumab | Viral antibodies | Epidermal growth factor | Imaging systems | Antibodies | Permeability | Drug therapy | Biopharmaceutics | Tumors | Antigens | Hematology | Laboratories | Toxicity | DNA topoisomerase | Polymerization | Clinical trials | Cytotoxicity | Breast cancer | ErbB-2 protein | Stomach cancer | Hypotheses | Antitumor agents | Xenografts | Antitumor activity | Lymphomas | Drug dosages | Payloads | Index Medicus | T‐DM | Original
Journal Article
Drug Metabolism and Disposition, ISSN 0090-9556, 01/2010, Volume 38, Issue 1, pp. 92 - 99
The aim of the current study is to identify the human cytochrome P450 (P450) isoforms involved in the two oxidative steps in the bioactivation of clopidogrel... 
MECHANISM-BASED INHIBITION | ANTIAGGREGATING ACTIVITY | POLYMORPHISMS | TICLOPIDINE | PHARMACOKINETICS | HEALTHY-SUBJECTS | PHARMACOLOGY & PHARMACY | PRASUGREL | PHARMACODYNAMICS | MONOCLONAL-ANTIBODIES | ATORVASTATIN | Microsomes - metabolism | Humans | Aryl Hydrocarbon Hydroxylases - genetics | Cytochrome P-450 Enzyme System - metabolism | Sulfaphenazole - pharmacology | Microsomes - drug effects | Cytochrome P-450 CYP3A - genetics | Cytochrome P-450 CYP1A2 - genetics | Antibodies - immunology | Omeprazole - pharmacology | Microsomes, Liver - enzymology | Platelet Aggregation Inhibitors - pharmacokinetics | Ticlopidine - pharmacokinetics | Oxidoreductases, N-Demethylating - metabolism | Aryl Hydrocarbon Hydroxylases - immunology | Oxidation-Reduction | Enzyme Inhibitors - pharmacology | Ticlopidine - analogs & derivatives | Oxidoreductases, N-Demethylating - immunology | Cytochrome P-450 CYP3A - metabolism | Cell Line, Tumor | Cytochrome P-450 Enzyme System - genetics | Theophylline - pharmacology | Kinetics | Cytochrome P-450 CYP2C9 | Theophylline - analogs & derivatives | Oxidoreductases, N-Demethylating - genetics | Glutathione - metabolism | Ketoconazole - pharmacology | Biotransformation - physiology | Cytochrome P-450 CYP1A2 Inhibitors | Microsomes, Liver - drug effects | Ticlopidine - metabolism | NADP - metabolism | Platelet Aggregation Inhibitors - metabolism | Cytochrome P-450 CYP3A - immunology | Cell Line | Aryl Hydrocarbon Hydroxylases - antagonists & inhibitors | Cytochrome P-450 CYP1A2 - immunology | Biocatalysis | Mephenytoin - analogs & derivatives | Cytochrome P-450 CYP1A2 - metabolism | Aryl Hydrocarbon Hydroxylases - metabolism | Mephenytoin - pharmacology | Antibodies - pharmacology | Cytochrome P-450 CYP3A Inhibitors | Cytochrome P-450 CYP2C19 | Clopidogrel | Cytochrome P-450 CYP2B6 | Index Medicus
Journal Article
Immunity, ISSN 1074-7613, 02/2019, Volume 50, Issue 2, pp. 477 - 492.e8
Resistance to checkpoint-blockade treatments is a challenge in the clinic. We found that although treatment with combined anti-CTLA-4 and anti-PD-1 improved... 
activation-induced cell death | IFN-γ | cancer | anti-CTLA-4 | anti-PD-1 | immunotherapy | RESPONSES | SOLID TUMORS | ANTI-CTLA-4 | IMMUNOTHERAPY | PD-1 BLOCKADE | IFN-GAMMA | COMBINED NIVOLUMAB | ACQUIRED-RESISTANCE | IMMUNOLOGY | CANCER | IPILIMUMAB | Humans | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Interferon-gamma - metabolism | T-Lymphocytes - metabolism | T-Lymphocytes - drug effects | Clonal Deletion - drug effects | Neoplasms, Experimental - immunology | Antibodies, Monoclonal - immunology | Antibodies, Monoclonal - pharmacology | Mice, Inbred C57BL | CTLA-4 Antigen - metabolism | Programmed Cell Death 1 Receptor - metabolism | Drug Resistance, Neoplasm - immunology | CTLA-4 Antigen - immunology | Clonal Deletion - immunology | Mice, Knockout | Animals | Tumor Burden - drug effects | Interferon-gamma - immunology | Cell Line, Tumor | T-Lymphocytes - immunology | Neoplasms, Experimental - metabolism | Programmed Cell Death 1 Receptor - immunology | CTLA-4 Antigen - antagonists & inhibitors | Neoplasms, Experimental - drug therapy | Interferon-gamma - pharmacology | Drug Resistance, Neoplasm - drug effects | Tumor Burden - immunology | Antigens | PD-1 protein | Secretion | Melanoma | Clinical trials | Lymphocytes T | Immune status | Metastasis | Cancer therapies | Immunity | Clinical outcomes | CTLA-4 protein | Immune checkpoint | Clonal deletion | Lymphocytes | Immunotherapy | γ-Interferon | Deletion | Interferon | Mutation | Tumors | Apoptosis
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 10/2016, Volume 22, Issue 20, pp. 5097 - 5108
Purpose: An anti-HER2 antibody-drug conjugate with a novel topoisomerase I inhibitor, DS-8201a, was generated as a new antitumor drug candidate, and its... 
ANTIBODY-DRUG CONJUGATE | ONCOLOGY | CLINICAL ONCOLOGY/COLLEGE | NEU ONCOGENE | METASTATIC BREAST-CANCER | MONOCLONAL-ANTIBODY | OVARIAN-CANCER | PANCREATIC ADENOCARCINOMA | MULTIDRUG-RESISTANCE | TRASTUZUMAB EMTANSINE | AMERICAN SOCIETY | Humans | Immunoconjugates - pharmacokinetics | Macaca fascicularis | Maytansine - pharmacology | Pancreatic Neoplasms - drug therapy | Immunoconjugates - pharmacology | Topoisomerase I Inhibitors - pharmacology | Antibodies, Monoclonal, Humanized - pharmacokinetics | Antineoplastic Agents - adverse effects | Antibodies, Monoclonal, Humanized - pharmacology | Female | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Receptor, ErbB-2 - antagonists & inhibitors | Receptor, ErbB-2 - immunology | Trastuzumab - pharmacology | Phosphorylation - drug effects | Proto-Oncogene Proteins c-akt - metabolism | Camptothecin - analogs & derivatives | Immunoconjugates - adverse effects | Camptothecin - pharmacokinetics | Antibodies, Monoclonal, Humanized - adverse effects | Camptothecin - adverse effects | Maytansine - analogs & derivatives | Rats | Breast Neoplasms - drug therapy | Checkpoint Kinase 1 - metabolism | Animals | Mice, Nude | Cell Line, Tumor | Cell Proliferation - drug effects | Mice | Histones - metabolism | Antibody-Dependent Cell Cytotoxicity - drug effects | Camptothecin - pharmacology | Index Medicus
Journal Article
Immunity, ISSN 1074-7613, 02/2019, Volume 50, Issue 2, p. 477
Resistance to checkpoint-blockade treatments is a challenge in the clinic. We found that although treatment with combined anti-CTLA-4 and anti-PD-1 improved... 
Cell death | Analysis | Immunotherapy | Melanoma | Disease susceptibility | Interferon | Biological response modifiers | T cells | Health aspects | Cancer
Journal Article
OncoImmunology, ISSN 2162-4011, 01/2019, Volume 8, Issue 1, pp. e1486953 - e1486953
Sipuleucel-T is the only FDA-approved immunotherapy for metastatic castration-resistant prostate cancer. The mechanism by which this treatment improves... 
immunomonitoring | prostate cancer | therapeutic vaccination | CD8 | checkpoint inhibition | Th1 | resistance | ONCOLOGY | IMMUNOTHERAPY | IMMUNOLOGY
Journal Article
Journal Article
Drug Delivery System, ISSN 0913-5006, 01/2016, Volume 30, Issue 5, pp. 454 - 464
As sulfa drug was found as the urinary metabolite of Prontosil in past times, early prodrugs were often discovered by chance. The prodrugs later on, however,... 
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.